Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21(WAF1/CIP1) and p16(CDKN4)) in human prostate cancers

Journal of Urology

Volumn 158, Issue 2, 1997, Pages 636-641

  Gotoh, Akinobu ^b   Kao, Chinghai ^b   Ko, Song Chu ^b   Hamada, Katsuyuki ^b   Liu, Ta Jen ^b   Chung, Leland W K ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b NONE

Author keywords

Gene therapy; P16(CDKN2); P21(WAF1 CIP1); P53; Tumor suppressor gene

Indexed keywords

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOGENICITY; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE CANCER; REGULATOR GENE; TUMOR SUPPRESSOR GENE;

EID: 0030757796     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64574-9     Document Type: Article

References (43)

1. Parker, S. L., Tong, T., Bolden, S. and Wingo, P. A.: Cancer statistics. CA Cancer J. Clin., 46: 5, 1996.
2. Huggins, C. and Hodges, C. V.: Studies on prostate cancer I. The effect of castration, of estrogen and of androgen injection on the normal and on the hyperplastic glands of dogs. Cancer Res., 1: 293, 1941.
3. Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hostetter, R., Cleary, K., Bigner, S. H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F. S., Weston, A., Modali, R., Harris, C. C. and Vogelstein, B.: Mutations in the p53 occur in diverse human tumor types. Nature (London), 342: 705, 1989.
4. Navone, N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L., Palmer, J. L., Nichols, W. L., von Eschenbach, A. and Conti, C.: p53 protein accumulation in the progression of human prostate carcinoma. J. Natl. Cancer Inst., 85: 1657, 1993.
5. Chen, P.-L., Chen, Y., Bookstein, R. and Lee, W.-H.: Genetic mechanisms of tumor suppression by the human p53 gene. Science, 250: 1576, 1990.
6. Diller, L., Kassel, J., Nelson, C. E., Gryka, M. A., Litwak, G., Gebhardt, M., Bressac, B., Ozturk, M., Baker, S. J., Vogelstein, B. and Friend, S. H.: p53 function as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol., 10: 5772, 1990.
7. Wang, N. P., To, H., Lee, W.-H. and Lee, E. Y.-H.: Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells. Oncogene, 8: 219, 1993.
8. Okamoto, A., Demetric, D. J., Spillare, E. A., Hagiwara, K., Hussain, S. P., Bennett, W. P., Forrester, K., Gerwin, B., Serrano, M., Beach, D. H. and Harris, C. C.: Mutations and altered expression of p16INK4 in human cancer. Proc. Natl. Acad. Sci. USA, 91: 11045, 1994.
9. Missero, C., Calautti, E., Eckner, R., Chen, J., Tsai, L. H., Livingston, D. M. and Dotto, G. P.: Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc. Natl. Acad. Sci. USA, 92: 5451, 1995.
10. Ko, S.-C., Gotoh, A., Thalmann, G. N., Zhau, H. E., Johnston, D. A., Zhang, W.-W., Kao, C. and Chung, L. W. K.: Molecular therapy with recombinant p53 adenovirus in an androgen independent, metastatic human prostate cancer model. Human Gene Therapy, 7: 1683, 1996.
11. Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M. and Smith, J. R.: Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res., 211: 90, 1994.
12. Xiong, Y., Zhang, H. and Beach, D.: Subunit rearrangement of the cycling-dependent kinase is associated with cellular transformation. Genes Dev., 7: 1572, 1993.
13. Serrano, M., Hannon, G. T. and Beach, D.: A new regulator motifin cell-cycle control causing specific inhibition of cycling D/CDK4. Nature (London), 366: 704, 1994.
14. Kamb, A.: Cell-cycle regulators and cancer. Trends Genet., 11: 136, 1995.
15. el Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. and Vogelstein, B.: WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817, 1993.
16. Vogelstein, B., Fearon, E. R., Kern, S. E., Hamilton, S. R., Preisinger, A. C. and Nakamura, Y.: Allelotype of colorectal carcinomas. Science, 244: 207, 1989.
17. Sato, T., Saito, H., Morota, R., Koi, S., Lee, J. H. and Nakamura, Y.: Allelotype of human ovarian cancer. Cancer Res., 51: 5118, 1991.
18. Solomon, E., Borrow, J. and Goddard, A. D.: Chromosome aberrations and cancer. Science, 254: 1153, 1991.
19. Morita, R., Ishikawa, J., Tsutsumi, M., Hikij, K., Tsukada, Y., Kamidono, S., Maeda, S. and Nakamura, Y.: Allelotype of renal cell carcinoma. Cancer Res., 51: 820, 1991.
20. Shiohara, M., El-deiry, W. S., Wada, M., Nakamaki, T., Takeuchi, S., Yang, R., Chen, D.-L., Vogelstein, B. and Koeffler, H. P.: Absence of WAF1 mutations in a variety of human malignancies. Blood, 84: 3781, 1994.
21. Tenan, M., Carrara, F., Didonato, S. and Finocchiaro, G.: Absence of mutations and identification of two polymorphisms in the sscp and sequence analysis of p21CK1 gene in malignant gliomas. Int. J. Cancer, 62: 115, 1995.
22. Bett, A. J., Prevec, L. and Graham, F. L.: Packaging capacity and stability of human adenovirus type 5 vectors. J. Virol., 67: 5911, 1993.
23. Jiang, H., Lin, J., Su, Z.-Z., Collart, F. R., Huberman, E. and Fisher, P. B.: Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene, 9: 3397, 1994.
24. Steinman, R. A., Hoffman, B., Iro, A., Guillouf, C., Liebermann, D. A. and El-Houseini, M. E.: Induction of p21 (WAF1/CIP1) during differentiation. Oncogene, 9: 3389, 1994.
25. Nobori, T., Miura, K., Wu, J. D., Lois, A., Takabashi, K. and Carson, D. A.: Deletion of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (London), 368: 753, 1994.
26. Kamb, A., Gruis, N. A., Weaver, F. J., Liu, Q., Harshman, K., Tavtigain, S. V., Stockert, E., Day, R. S., Johnson, B. E. and Skolnick, H. M.: A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264: 436, 1994.
27. Medema, R. H., Herrera, R., Lam, F. and Weinberg, R. A.: Growth suppression by p16ink4 requires functional retinoblastoma protein. Proc. Natl. Acad. Sci. USA, 92: 6289, 1995.
28. Thalmann, G. N., Anizinis, P. E., Chang, S. M., Zhau, H. Y. E., Kim, E., Hopwood, V. L., Pathak, S., von Eschenbach, A. C. and Chung, L. W. K.: Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res., 54: 2577, 1994.
29. Wu, H. C., Hsieh, J. T., Gleave, M. E., Brown, N. M., Pathak, S. and Chung, L. W. K.: Derivation of androgen-independent human LNCaP Prostatic cancer cell sublines: role of bone stromal cells. Int. J. Cancer, 57: 406, 1994.
30. Gravrieli, Y., Sherman, Y. and Ben-Sasson, S. A.: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol., 119: 493, 1992.
31. Kleinerman, D. I., Zhang, W. W., Lin, S. H., Nguyen, T. V., von Eschenbach, A. C. and Hsieh, J. T.: Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a pre-clinical study. Cancer Res., 55: 2831, 1995.
32. Kuerbritz, S. J., Plunkett, B. S., Walsh, W. V. and Kastan, M. B.: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491, 1992.
33. Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D. F. P., Prives, C. and Vogelstein, B.: Identification of p53 as a sequence-specific DNA-binding protein. Science, 252: 1708, 1991.
34. Funk, W. D., Park, D. T., Karas, R. H., Wright, W. E. and Shay, J. W.: A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol., 12: 2866, 1992.
35. Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R. and Prives, C.: Wild-type p53 activates transcription in vitro. Nature (London), 358: 83, 1992.
36. Waldman, T., Kinzler, K. W. and Vogelstein, B.: p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res., 55: 5187, 1995.
37. Zhang, W.-W., Fang, X., Mazur, W., French, B. A., Georges, R. N. and Roth, J. A.: High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Therapy, 1: 5, 1994.
38. Liu, T., Zhang, W.-W., Taylor, D. L., Roth, J. A., Goepfert, H. and Clayman, G. L.: Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via recombinant adenovirus. Cancer Res., 54: 3662, 1994.
39. Fricker, J.: Hepatocellular carcinoma and p53 gene therapy. Mol. Med. Today, 2: 361, 1996.
40. Caldas, C., Hahn, S. A., Da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J. and Kern, S. E.: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genetics, 8: 27, 1994.
41. Spruck, C. H., Gonzalez-Zulueta, M., Shibata, A., Simoneau, A. R., Lin, M.-F., Gonzales, F., Tsai, Y. C. and Jones, P. A.: p16 gene in unclutured tumours. Nature (London), 370: 183, 1994.
42. Hussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Tucker, M. A. and Dracopoli, N. C.: Germline p16 mutations in familial melanoma. Nature Genetics, 8: 15, 1994.
43. Wang, X. W., Vermeulen, W., Coursen, J. D., Gibson, M., Lupold, S. E., Forrester, K., Xu, G., Elmore, L., Yeh, H., Hoeijmakers, J. H. J. and Harris, C. C.: The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes & Development, 10: 1219, 1996.